47 results about "Veterinary Patient" patented technology

A device and method for cutting or ablating tissue in a human or veterinary patient includes an elongate probe having a distal end, a tissue cutting or ablating apparatus located adjacent within the distal end, and a tissue protector extending from the distal end. The protector generally has a first side and a second side and the tissue cutting or ablating apparatus is located adjacent to the first side thereof. The distal end is structured to be advanceable into tissue or otherwise placed and positioned within the patient's body such that tissue adjacent to the first side of the protector is cut away or ablated by the tissue cutting or ablation apparatus while tissue that is adjacent to the second side of the protector is not substantially damaged by the tissue cutting or ablating apparatus.

Heat exchanger-equipped catheters and related methods that are useable for changing or maintaining at least a portion of the body of a human or veterinary patient at a desired temperature and for the measurement of cardiac output or blood flow rate within a blood vessel, without the need for introduction of saline solution or any other foreign substance into the patient's blood.

This invention provides, e.g., a catheter with a threaded loop type snare tool for retrieval of objects from blood vessels and / or body cavities. The snare tool of the invention provides, e.g., independently maneuverable probe wires and snare wires to encircle and releasably snare foreign objects inside human and veterinary patients. The invention further provides methods of using the catheter of the invention to retrieve objects from patients.

Methods and apparatus for treating or preventing endoleaks after an endovascular graft (e.g., a stent, tubular graft, stent-graft, coated stent, covered stent, intravascular flow modifier or other endovascular implant that affects, limits or prevents blood flow into a vascular defect such as an aneurysm, arterio-venous fistula, arterio-venous malformation, vessel wall perforation, etc.) has been implanted in the vasculature of a human or veterinary patient. An expansile polymeric material, such as a swellable polymer (e.g., a hydrogel), a flexible or elastomeric polymer foam (e.g. silicone, polyurethane, etc.) or a carrier member (e.g, a coil, filament, wire, etc) that carries a quantity of such expansile polymer is delivered into a perigraft space (i.e., space between the endovascular graft and the surrounding blood vessel wall) such that the polymeric material expands in situ to substantially fill the perigraft space or a portion thereof. The expansile polymeric material is delivered into he perigraft space through a catheter and / or cannula that is placed prior to, during or after the implantation of the endovascular graft. The invention includes an injector apparatus that is useable to deliver the expansile polymeric material through the wall of a previously implanted graft. After delivery into the perigraft space, the expanded polymeric material expands so as to fill all or an intended portion of the perigraft space in a manner that substantially prevents additional blood from leaking or flowing into such perigraft space. One type of blood-absorbing, porous, expansile polymeric material useable in this invention is a super-expansile hydrogel.

Compositions of matter that comprise one or more conformational epitopes found on amyloid peptide aggregates, antibodies to such epitopes and methods for making and using the compositions, eptitopes and / or antibodies. The invention includes synthetic or isolated compositions that contain or consist of certain conformational epitopes that are found on peptide aggregates (e.g., toxic peptide aggregates) present in human or veterinary patients who suffer from, or who are likely to develop, amyloid diseases (e.g., Alzheimer's Disease). The invention includes methods for the detection, treatment and prevention of diseases in humans or animals, using such compositions. The invention further includes antibodies which bind to the conformational epitopes as well as methods for making such antibodies and methods for the detection, treatment and prevention of diseases and / or identification of potential therapies (e.g., drug screening) using such antibodies.

Medical devices for insertion into the body of human or veterinary patients, wherein the device comprises a) a working element (e.g. a wire, a guidewire, a tube, a catheter, a cannula, a scope (e.g., rigid or flexible endoscope, laparoscope, sigmoidoscope, cystoscope, etc.) a probe, an apparatus for collecting information from a location within the body (e.g., an electrode, sensor, camera, scope, sample withdrawal apparatus, biopsy or tissue sampling device, etc.) which has an outer surface and b) a continuous or non-continuous coating on the outer surface of the working element. The outer surface of the working element is prepared to create a surface topography which promotes mechanical or frictional engagement of the coating to the working element. In some embodiments the coating is a lubricious coating, such as a fluorocarbon coating or a hydrogel that becomes lubricious when contacted by a liquid. In some embodiments, the coating may expand as swell. Also disclosed as methods for manufacturing such devices.

A system and method for determining the volume of oxygen taken up by the lungs of a human or veterinary patient. A closed ventilation circuit is connected to a spirometric device, which contains a quantity of oxygen. As oxygen is taken up by the patient, an equivalent volume of oxygen passes from the spirometric device into the ventilation circuit. The volume of oxygen that moves from the spirometric device may thus be measured as an indication of the volume of oxygen that has been taken up by the patient. In some embodiments, a source of make-up oxygen is connected to the ventilation circuit and the flow of make-up oxygen is adjusted as necessary to maintain a substantially constant volume of oxygen in the spirometric device. The volume of make-up oxygen is measured and serves as an indication of the amount of oxygen taken up by the patient. A valve may be used to close the spirometric device off from the ventilation circuit during all but a part of the ventilation cycle (e.g., all but the late expiratory phase) to prevent substantial pressure or movement excursions within the spirometric device

The present invention relates to a motion monitoring apparatus and method for monitoring a patient under medical care. A sensor arrangement is provided in the form of a pad which the patient lies on. The sensor arrangement provides a signal which can be monitored to observe motion of the patient and provide an alarm should the motion meet certain predetermined conditions. The invention is particularly applicable for monitoring patients under sedation, recovering from anaesthesia, or in intensive care. The device is particularly useful for veterinary patients.

Compositions of matter and methods wherein chalcone and flavone derivatives are administered to human or veterinary patients for the treatment of bladder or urinary tract cancer. Compounds of the invention include 2′-hydroxy-4,4′,6′-trimethoxychalcone (Flavokawain A).

The present invention relates to the field of medical devices used in the procedures of orotracheal or nasotracheal intubation. Oral or nasal endotracheal intubation procedures are commonly employed to secure a controlled airway and to deliver inhalant oxygen, anesthetic gases, and other therapeutic agents into the trachea and lungs of human and veterinary patients. Such intubation procedures carry a significant risk of dental injury resulting from contact between the laryngoscope blade used for visualization during intubation. The present invention provides an apparatus to reduce dental injury including a modified laryngoscope blade and a disposable insert which is designed to be received and retained in a single step by the modified laryngoscope blade. The disposable insert may be quickly secured by the user, and reduces both direct pressure and shear forces on the maxillary incisor teeth when the laryngoscope blade is placed in a patient's mouth during intubation.

Systems and methods for use in providing hyperbaric oxygen therapy (“HBOT”) sessions to veterinary patients includes providing HBOT chambers specifically adapted for use with veterinary patients. HBOT chambers are adapted with a rail mounted platform upon which one or more animals may be supported and confined within an enclosure during the application of HBOT. Viewing ports are provided at the appropriate level to allow the pets being treated to see out from their position within the chamber. The system is provided with a closed circuit video system including a plurality of chamber mounted cameras configured allow for remote monitoring of the animals within the chamber, and a room mounted camera configured to allow for remote monitoring of the chamber and surrounding environment. Remote central station monitoring allows for widespread deployment of hyperbaric chambers in accordance with a business method wherein revenue is generated on per-use and / or per-patient basis.

An embodiment of a portable veterinary medical record system includes a portable memory storage device that contains both a data structure for medical records and a set of processing instructions related to use of the device. The set of instructions may include authentication instructions for user authentication; instructions for data storage; instructions for updating medical record information; instructions for recognizing host veterinary patient information management software; and instructions for displaying medical record information, for example. According to the embodiment, the set of instructions are automatically executed by a computer that couples with the device. An embodiment provides for authentication cards and authentication PINs to facilitate double-key authentication. The device may be retained by an animal owner. Such retention makes records more readily available in an emergency or during travel. In addition, owner retention of the device represents a practical acknowledgement of veterinary medical record co-ownership.

The present invention relates to allergy vaccines and methods of treating and / or preventing asthma, and allergic conditions. The invention is based on the discovery that inhibiting the ligand / receptor interactions involving, e.g., IgE, IL-3, IL-4, IL-5, IL-6, IL-10, IL-13, interferon-alpha, histamine, leukotriene, and their respective receptors, inhibits production of IgE thereby treating or preventing such diseases or conditions. Competitive inhibition of such receptor / ligand interactions is accomplished by immunizing a human or veterinary patient with the interleukin, interferon-alpha, histamine, leukotriene, their receptors, in any combination. Also, the invention relates to inhibiting receptor / ligand interactions involved in IgE production by competitively inhibiting such interactions by administering antibodies to the ligands, receptors, or both, as well as by administering analogs of the receptors (e.g., soluble receptors not associated with a cell).

The present invention relates to allergy vaccines and methods of treating and / or preventing asthma, and allergic conditions. The invention is based on the discovery that inhibiting the ligand / receptor interactions involving, e.g., IgE, IL-3, IL-4, IL-5, IL-6, IL-10, IL-13, interferon-alpha, histamine, leukotriene, and their respective receptors, inhibits production of IgE thereby treating or preventing such diseases or conditions. Competitive inhibition of such receptor / ligand interactions is accomplished by immunizing a human or veterinary patient with the interleukin, interferon-alpha, histamine, leukotriene, their receptors, in any combination. Also, the invention relates to inhibiting receptor / ligand interactions involved in IgE production by competitively inhibiting such interactions by administering antibodies to the ligands, receptors, or both, as well as by administering analogs of the receptors (e.g., soluble receptors not associated with a cell).

After Hours Monitoring is a method of use system for monitoring a veterinary patient comprising: a monitor which is capable of receiving signals of low-power radio frequencies of physiological data from multiple wireless sensors; a remote surveillance system for visual observation of said patient.

Devices, systems and methods for treating disorders characterized by low cardiac output. The devices, systems and methods use intra-aortic balloon counterpulsation in combination with hypothermia of all or a portion of a human or veterinary patient's body to improve coronary perfusion and cardiac output. To effect the hypothermia, a heat exchange catheter may be positioned in the a patient's vasculature separately from the intra-aortic balloon counterpulsation catheter. Alternatively, a combination Intra-aortic balloon counterpulsation / heat exchange catheter may be utilized. Such combination catheter comprises a) a catheter sized for insertion into the aorta, b) a counterpulsation balloon and c) a heat exchanger. A drive / control system receives temperature and electrocardiograph signals and drives the inflation / deflation of the counterpulsation balloon as well as the heating / cooling of the heat exchanger.

Compositions of matter comprising 5-phenylalkoxypsoralen compounds and their method of synthesis and use. The compounds are useable to treat diseases or disorders in human or veterinary patients, including autoimmune diseases such as multiple sclerosis. The compounds inhibit potassium channels, including the Kv1.3 channel and at least some of the therapeutic effects of such compounds may be due at least in part to potassium channel inhibition.

Compositions, prodrugs and methods for inhibiting neural Nitric Oxide Synthase (nNOS). By inhibiting nNOS, the compounds, prodrugs and methods of the presnet invention are useable to treat or prevent disorders in human or veterinary patients that are caused, mediated or agrevated by Nitric Oxide within the body.

Devices for containing exposed internal body parts during insertion into the body of a human or veterinary patient are provided. The devices include a surgical pouch for containing the exposed internal body parts. The devices also include one or more sealing elements disposed on the surgical pouch between the proximal end and the distal end of the surgical pouch such that a section of the pouch is closed off when each sealing element is sealed. Also provided are methods for containing exposed internal body parts of a human or veterinary patient during insertion into the body of the patient.

A fluid characteristic indicator for measuring and indicating a characteristic of a body fluid from a medical or veterinary patient has a generally tubular housing with a suction port at a proximal end and a fluid inlet port at the distal end. An fluid characteristic indicating element is disposed in the housing. A diffuser is provided in the housing to support the indicating element and direct fluid from the inlet port toward the indicating element. The diffuser has at least one fluid channel to direct fluid toward the indicating element. The fluid channel may take the form of a spiral or helix. Alternatively, the diffuser may have a plurality of longitudinal fluid channels. the housing and the diffuser may have additional structures forming channels that cooperatively direct fluid toward the indicating element. The diffuser and may occupy nearly all the interior volume of the housing. Control of the fluid flow makes exposure and saturation of the indicator more accurate, avoids spurious indications due to the color of the fluid itself reduces the amount of fluid sample needed to obtain an indication or measurement.

This invention relates to time-release capsules administered in beverage preparations. The present invention may be used for administration of delayed-release flavor or color enhancement of the beverage preparation. It may also be used for the oral administration of pharmaceutical compounds, vitamins, or other active compounds, including herbal ingredients, to a person or animal in a liquid beverage. This invention solves several problems associated with the blending of complex drinks and taste habituation wherein the taste intensity of a drink decreases with time. It also solves several practical problems associated with administration of compounds to a person or veterinary patient, including reduction of efficacy due to manufacturing issues, suboptimal dissolution in the digestive system, and administration of an unpleasant oral compound in a form that is displeasing to taste.

A device and method for cutting or ablating tissue in a human or veterinary patient includes an elongate probe having a distal end, a tissue cutting or ablating apparatus located adjacent within the distal end, and a tissue protector extending from the distal end. The protector generally has a first side and a second side and the tissue cutting or ablating apparatus is located adjacent to the first side thereof. The distal end is structured to be advanceable into tissue or otherwise placed and positioned within the patient's body such that tissue adjacent to the first side of the protector is cut away or ablated by the tissue cutting or ablation apparatus while tissue that is adjacent to the second side of the protector is not substantially damaged by the tissue cutting or ablating apparatus.

Methods for treating disorders of the eye and / or disorders of a nerve in a human or veterinary patient by delivering to the patient a therapeutically effective amount of a compound selected from the group of; urea, urea derivatives, thiourea, thiourea derivatives, guanidine, guanidine derivatives and compounds having General Formula I as set forth herein. For ophthalmic applications, the compound may be delivered by intravitreal injection such that the compound causes vitreal liquefaction, posterior vitreoretinal detachment and other affects.